Meeting
2021 ASCO Annual Meeting
First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.
Presenter
Luis A Meza, MD
City of Hope Comprehensive Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03829111
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4513)
DOI
10.1200/JCO.2021.39.15_suppl.4513
Abstract #
4513
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).
Speaker: Matthew D. Tucker, MD
Videos & Slides
2019 ASCO Annual Meeting
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).
Speaker: Jianjun Gao, MD, PhD
Videos & Slides
2018 ASCO Annual Meeting
Chair
Speaker: Amishi Yogesh Shah, MD
Speaker: Lewis E Foxhall, MD